A5029225508- Peroxisome Proliferator-Activated Receptors
- Ubiquitin and proteasome pathways
- Inflammatory mediators and NSAID effects
- Metabolism and Genetic Disorders
- Nuclear Receptors and Signaling
- Histone Deacetylase Inhibitors Research
- Macrophage Migration Inhibitory Factor
- Biochemical and Structural Characterization
- Platelet Disorders and Treatments
- Advanced Breast Cancer Therapies
- Sphingolipid Metabolism and Signaling
- Rabies epidemiology and control
- Estrogen and related hormone effects
- Mitochondrial Function and Pathology
- Cancer, Hypoxia, and Metabolism
- Boron Compounds in Chemistry
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Immune cells in cancer
- Antiplatelet Therapy and Cardiovascular Diseases
- GDF15 and Related Biomarkers
- Plant biochemistry and biosynthesis
- Cholesterol and Lipid Metabolism
- Cancer, Lipids, and Metabolism
- Galectins and Cancer Biology
Newcastle University
2020-2024
Newcastle upon Tyne Hospital
2024
University of Reading
2012-2014
Centre de Génétique Moléculaire
2001
Centre National pour la Recherche Scientifique et Technique (CNRST)
2001
Centre National de la Recherche Scientifique
2001
BMDMs are a key model system to study macrophage biology in vitro. Commonly used methods differentiate macrophages from BM treatment with either recombinant M-CSF or the supernatant of L929 cells, which secrete M-CSF. However, little is known about composition cell-conditioned media (LCCM) and how it affects BMDM phenotype. Here, we quantitative mass spectrometry characterise kinetics protein secretion cells over 2-wk period, identifying 2,193 proteins. Whereas very abundant LCCM, identified...
Trilaciclib, a CDK4/6 inhibitor, was approved as myeloprotective agent for protecting bone marrow from chemotherapy-induced damage in extensive-stage small cell lung cancer (ES-SCLC). This is achieved through the induction of temporary halt cycle cells. While it has been studied various types, its potential haematological cancers remains unexplored. research aimed to investigate efficacy trilaciclib cancers. Utilizing mass spectrometry-based proteomics, we examined alterations induced by...
Abstract —Anderson’s disease is a rare, hereditary hypocholesterolemic syndrome characterized by chronic diarrhea, steatorrhea, and failure to thrive associated with the absence of apo B48–containing lipoproteins. To further define molecular basis disease, we studied 8 affected subjects in 7 unrelated families North African origin after treatment low-fat diet. Lipid loading intestinal biopsies persisted, but pattern extent was variable among patients. Electron microscopy showed...
Ubiquitylation is an elaborate post-translational modification involved in all biological processes. Its pleotropic effect driven by the ability to form complex polyubiquitin chain architectures that can influence functions. In this study, we optimised sample preparation and chromatographic separation of Ubiquitin peptides for Absolute Quantification Parallel Reaction Monitoring (Ub-AQUA-PRM). Using refined Ub-AQUA-PRM assay, were able quantify ubiquitin types 10-min LC-MS/MS runs. We used...
Inflammatory responses are important in cancer, particularly the context of monocyte-rich aggressive myeloid neoplasm. We developed a label-free cellular phenotypic drug discovery assay to identify anti-inflammatory drugs human monocytes derived from acute leukemia (AML), by tracking several features ionizing only 2500 cells using matrix-assisted laser desorption/ionization-time flight (MALDI-TOF) mass spectrometry. A proof-of-concept screen showed that BCR-ABL inhibitor nilotinib, but not...
ABSTRACT Trilaciclib, a CDK4/6 inhibitor, was approved as myeloprotective agent for protecting bone marrow from chemotherapy-induced damage in extensive-stage small cell lung cancer (ES-SCLC). This is achieved through the induction of temporary halt cycle cells. While it has been studied various types, its potential haematological cancers remains unexplored. research aimed to investigate efficacy trilaciclib cancers. Utilizing mass spectrometry-based proteomics, we examined alterations...
Immortalised cell lines that mimic their primary counterparts are fundamental to research, particularly when large numbers required. Here, we report immortalisation of bone marrow-derived macrophages (iBMDMs) using the J2 virus resulted in loss a protein interest, MSR1, WT cells by an unknown mechanism. This led us perform in-depth mass spectrometry-based proteomic characterisation common murine macrophage (J774A.1, RAW264.7, and BMA3.1A7), comparison with iBMDMs, as well BMDMs from both...
Abstract Objectives The search for agents that are capable of preventing restenosis and reduce the risk late thrombosis is utmost importance. In this study we aim to evaluate in vitro effects ibuprofen on proliferation migration human coronary artery smooth muscle cells endothelial cells. Methods Cell was evaluated by trypan blue exclusion. assessed wound-healing ‘scratch’ assay time-lapse video microscopy. Protein expression immunoblotting, morphology immunocytochemistry. involvement PPARγ...
Abstract Bone marrow-derived macrophages (BMDMs) are a key model system to study macrophage biology in vitro . Commonly used methods differentiate from bone marrow treatment with either recombinant M-CSF or the supernatant of L929 cells, which secrete M-CSF. However, little is known about composition cell conditioned media (LCCM) and how it affects BMDM phenotype. Here, we quantitative mass spectrometry characterise kinetics protein secretion cells over two-week period, identifying 2,193...
<h3>Introduction</h3> Drug-eluting stents (DES) have reduced the rates of restenosis to less than 10%; however, increased incidence late in-stent thrombosis, is now a major clinical problem using DES for its consequences in terms morbidity and mortality. Interference with process re-endothelialization appears play role this latent complication. Thus, search molecular compounds capable preventing that also can reduce risk thrombosis utmost importance. Previously, we shown certain...
Re-occlusion of blood vessels following percutaneous coronary intervention with stenting (in stent stenosis) occurs in 5–10% patients receiving drug-eluting stents. the treated vessel is observed when vascular smooth muscle cells (VSMCs) proliferate and migrate response to injury, inflammation impaired healing endothelial cell layer. Novel drug eluting stents that reduce permit repair whilst preventing detrimental VSMC proliferation migration might occurrence restenosis. We previously have...